# OnCo record ryz101 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ryz101/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ryz101" ;
  schema:name "Actinium-225 DOTATATE"@en ;
  schema:description "An alpha-particle version of Lutathera for neuroendocrine tumours that have stopped responding to the beta version."@en ;
  schema:url <https://onco.cc/drugs/ryz101/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=RYZ101> ;
  onco:status "phase-3" ;
  onco:modality "Targeted alpha therapy" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/rayzebio/> ;
  onco:trials <https://onco.cc/trials/nct06590857/> .